Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Takeda
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01467713
First received: November 4, 2011
Last updated: July 18, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to determine the efficacy and safety of ramelteon, once nightly before bedtime (QHS), sublingual (SL), in the maintenance treatment of Bipolar I Disorder in adult patients.


Condition Intervention Phase
Bipolar Disorder
Drug: Ramelteon SL
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Time from Randomization to Relapse in the Maintenance Treatment of Bipolar I Disorder [ Time Frame: Randomization to 9 months double-blind treatment period. ] [ Designated as safety issue: No ]
    The time from randomization to relapse over 9 months double-blind treatment period as determined by the Primary Investigator (PI) or defined by any of the following criteria: depression [Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥16]; mania/hypomania [Young Mania Rating Scale (YMRS) total score ≥14]; mixed episode [MADRS score ≥16 and YMRS total score ≥14]; or, whether participant receives psychiatric hospitalization for bipolar disorder, electroconvulsive therapy or any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes.


Secondary Outcome Measures:
  • Time from Randomization to Relapse due to Depression, Psychiatry Hospitalization for Depression, Electroconvulsive Therapy Administration or Medication Change to Treat Depressive Episode [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    Relapse due to depression is determined by any of the following criteria during the 9-month double-blind treatment period: PI judgment, MADRS ≥16, psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of depressive episodes)."

  • Time from Randomization to Relapse due to Mania/Hypomania or Mixed Episode [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    Relapse due to mania/hypomania or mixed episode is determined by any of the following criteria: PI judgment, mania/hypomania [YMRS ≥16], mixed episode [MADRS ≥16 and YMRS ≥16], psychiatry hospitalization, ECT or any psychotropic medication change prescribed for the treatment of mania/hypomania or mixed episodes.

  • Time from Randomization to Relapse in Depression [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    The time from randomization to relapse event over 9 month double-blind treatment period in depression, determined by the PI judgement and/or a MADRS score ≥16. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.

  • Time from Randomization to Relapse in Mania/Hypomania [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    Relapse in mania/hypomania is determined by the primary investigator (PI) judgement and/or a YMRS total score ≥14. YMRS is a 11 item scale with four items scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe) with higher scores reflecting greater levels of mania. The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.

  • Time from Randomization to Relapse in Mixed Episode [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    Relapse in Mixed episode is determined by PI judgement and/or MADRS score ≥16 and YMRS total score ≥14. MADRS is a 10-item scale that measures overall severity of depressive symptoms rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. YMRS is a four item scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.

  • Time from Randomization to Relapse with Psychiatric Hospitalization for Bipolar Disorder [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    The time from randomization to relapse event over 9 months double-blind treatment period due to psychiatric hospitalization for bipolar disorder.

  • Time from Randomization to Relapse with Electroconvulsive Therapy Administration [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    The time from randomization to relapse event over 9 months double-blind treatment period with electroconvulsive therapy.

  • Time from Randomization to Relapse with any Psychotropic Medication Change Prescribed for the Treatment of Depression, Mania/Hypomania or Mixed Episodes [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    The time from randomization to relapse event over 9 months double-blind treatment period due to any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episode(s).

  • Time from Randomization to Withdrawal for Any Reason. [ Time Frame: Randomization to 9 months double-blind treatment period ] [ Designated as safety issue: No ]
    The time from randomization to withdrawal over 9 months double-blind treatment period. Withdrawal includes pretreatment event/adverse event; liver function test abnormalities; major protocol deviation; lost to follow-up; voluntary withdrawal; study termination; pregnancy; lack of efficacy; participant has a depressive, mania/hypomania or mixed episode; is hospitalized for psychiatric reasons; receives electroconvulsive therapy for bipolar disorder; receives any psychotropic medication change prescribed for the treatment of depression, mania/hypomania or mixed episodes; or any other reason.

  • Quality of Life, Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) total score at Month 1, 2, 3, 4, 5, 6, 7, 8 and Month 9. [ Time Frame: Baseline and Months 1, 2, 3, 4, 5, 6, 7, 8 and Month 9. ] [ Designated as safety issue: No ]
    Q-LES-Q-SF is a self-administered questionnaire to assess the degree of enjoyment and satisfaction experienced by patients in various areas of daily functioning. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes relative to baseline indicate improved quality of life.


Estimated Enrollment: 640
Study Start Date: January 2012
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramelteon SL (Dose 1) QHS Drug: Ramelteon SL
Ramelteon SL tablets, sublingual, once every night at bedtime for up to 9 months.
Other Names:
  • TAK-375
  • TAK-375SL
Experimental: Ramelteon SL (Dose 2) QHS Drug: Ramelteon SL
Ramelteon SL tablets, sublingual, once every night at bedtime for up to 9 months.
Other Name: TAK-375SL
Experimental: Ramelteon SL (Dose 3) QHS Drug: Ramelteon SL
Ramelteon SL tablets, sublingual, once every night at bedtime for up to 9 months.
Other Name: TAK-375SL
Placebo Comparator: Placebo QHS Drug: Placebo
Ramelteon SL placebo-matching tablets, sublingual, once every night at bedtime for up to 9 months.

Detailed Description:

TAK-375SL (ramelteon sublingual formulation) is being developed by Takeda Pharmaceutical Company Limited as an adjunctive treatment in the maintenance therapy of bipolar I disorder.

Participants will be seen twice a month for the first two months and then once every month up to the end of the 9-month treatment period. Participants who complete the 9-month treatment period will have a follow-up visit approximately seven days after the last visit. A safety followup phone call will be made 30 days after completion of the 9-month treatment period.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant suffers from bipolar I disorder, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria and is confirmed by the Structured Clinical Interview for DSM Disorders (SCID).
  4. The participant is a man or woman aged between 18 and 75 years, inclusive.
  5. The participant has an identified caregiver or person responsible (e.g. family member, spouse, case worker or nurse at a residential living (facility) that is considered reliable by the investigator.
  6. The most recent mood episode (depression, mania, mixed episode) is within the past 9 months from screening.
  7. The participant has been in remission in the opinion of the PI for at least 8 weeks prior to baseline from their most recent mood episode.
  8. The participant has a MADRS total score ≤12 at the Screening and Baseline visits.
  9. The participant has a YMRS score of ≤10 both at the Screening and Baseline visits.
  10. The participant has a Clinical Global Impression Scale - Severity (CGI-S) score of ≤2 at the Screening and Baseline visits.
  11. Hamilton Rating Scale for Anxiety (HAM-A) score is ≤21 at Screening and Baseline visits.
  12. The participant's medications for bipolar I disorder are stable i.e., no dose adjustment has been made for at least 8 weeks prior to the randomization
  13. A male subject who is nonsterilized* and sexually active with a female partner of childbearing potential agrees to use adequate contraception* from signing of informed consent through the duration of the study and for 30 days after the last dose.
  14. A female subject of childbearing potential* who is sexually active with a non sterilized male partner agrees to use routinely adequate contraception* from signing of informed consent throughout the duration of the study and for 30 days after the last dose.

Exclusion Criteria:

  1. The participant has received any investigational compound <30 days before Screening or 5 half-lives prior to Screening.
  2. The participant has ever received ramelteon in a previous clinical study or has ever used ramelteon.
  3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. The participant has one or more of the following:

    • Any current psychiatric disorder which is the primary focus of treatment other than bipolar I disorder as defined in the DSM-IV-TR, as assessed by the SCID.
    • Current or history of: schizophrenia or any other psychotic disorder, including major depression with psychotic features, bipolar depression with psychotic features (with the exception of psychosis associated with a manic or mixed episode), obsessive-compulsive disorder (OCD), mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Current diagnosis or history of alcohol or other substance abuse (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at three months from the day of screening (Participant must also have negative urine drug screen at Screening and Baseline; only exception is for benzodiazepines and opiates provided the participant has a valid prescription).
    • Current diagnosis or history of alcohol or other substance dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at six months from the day of screening.(Participant must also have negative urine drug screen at Screening and Baseline; only exception is for benzodiazepines and opiates provided the participant has a valid prescription).
    • Presence or history of a clinically significant neurological disorder (including epilepsy) as determined by the investigator.
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    • Any Axis II disorder that might compromise the study.
    • History of Rapid Cycling bipolar disorder: Patients who have more than 8 episodes of mood disorder per year.
  5. The participant experienced the first episode of mood disorder after the age of 65 years.
  6. The participant is on any other medications other than antidepressants (except fluvoxamine), mood stabilizers (lithium, valproate, lamotrigine), or atypical antipsychotics (risperidone, lithium and/or valproate, the levels should be in the specified range: lithium (serum levels up to 1.2 mEq/L); valproate (serum levels up to 125 mcg/ml) at screening.
  7. The participant has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
  8. The participant has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plans to initiate such therapy during the study (supportive therapy, marital therapy and bereavement counseling are allowed).
  9. The participant has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
  10. The participant is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study.
  11. The participant has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance.
  12. The participant has a history or current diagnosis of Fibromyalgia, Chronic Fatigue Syndrome, Chronic Pain Syndrome and Sleep apnea.
  13. The participant has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.
  14. The participant has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:

    • A serum creatinine value >1.5 times the upper limits of normal (xULN).
    • A serum total bilirubin value >1.5 xULN.
    • A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 xULN.
  15. The participant has glycosylated hemoglobin (HbA1C) ≥7% at screening and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known diabetes are not excluded.
  16. The participant has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. NOTE: T4 will be checked if TSH is out of range. If T4 is abnormal the participant will be excluded.
  17. The participant has clinically significant abnormal vital signs as determined by the investigator.
  18. The participant has an abnormal electrocardiogram as determined by the central reader and confirmed as clinically significant by the investigator.
  19. The participant has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  20. The participant has a positive urine drug screen. NOTE: Positive urine drug screens for benzodiazepines and opiates for which the participant has a valid prescription will be allowed.
  21. The subject has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  22. The subject has a positive urine drug screen. NOTE: Positive urine drug screens for benzodiazepines and opiates for which the subject has a valid prescription will be allowed.
  23. The subject, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01467713

Contacts
Contact: Takeda Study Registration Call Center 800-778-2860 medicalinformation@tpna.com

  Show 107 Study Locations
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Clinical Science Takeda
  More Information

Additional Information:
No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01467713     History of Changes
Other Study ID Numbers: TAK-375SL_203, U1111-1124-4675
Study First Received: November 4, 2011
Last Updated: July 18, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Disease
Bipolar Disorder
Pathologic Processes
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 18, 2014